Ignite Creation Date:
2024-05-05 @ 4:49 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00327652
Status:
COMPLETED
Last Update Posted:
2008-04-24
First Post:
2006-05-17
Brief Title:
Study of Safety and Tolerability of Intravenous CRS-100 in Adults With Carcinoma and Liver Metastases
Sponsor:
Anza Therapeutics Inc
Organization:
Anza Therapeutics Inc
Study Overview
Official Title:
Phase 1 Dose-Escalation Study of Safety and Tolerability of Intravenous CRS-100 in Adults With Carcinoma and Liver Metastases
Status:
COMPLETED
Status Verified Date:
2008-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This clinical trial evaluated the safety and tolerability of CRS-100 an investigational agent containing a live-attenuated strain of Listeria monocytogenes Lm CRS-100 is attenuated by genetic modification to limit cell to cell spread and invasion of liver cells These attenuations result in decreased virulence of CRS-100 in mice but retain the ability of the investigational agent to stimulate immunity in test animals and generate anti-tumor activity in mice The primary objective of this study was to determine the maximum tolerated dose MTD and to explore the safety profile of a single intravenous dose of CRS-100 in consenting volunteers Immunological response to CRS-100 and tumor status of study participants were also measured Participation in this first clinical trial with CRS-100 was restricted to adults with carcinoma refractory to standard treatment or for whom no standard treatment is available and who additionally had liver metastases
Detailed Description:
Patients who consented to participate in the study were evaluated for eligibility according to their medical history physical examination blood testing and computed tomography CT scan of thorax abdomen and pelvis Those patients who qualified for the study received a single intravenous dose of CRS-100 on study day 1 after which they remained in the hospital for five days for safety monitoring of health status including serial blood collections Study participants returned for out-patient follow-up for further blood tests and additional monitoring of safety and immune response to CRS-100 At day 56 after administration of CRS-100 participants had a repeat CT scan to measure tumor size and they were then discharged from the study
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None